{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:37:35Z","timestamp":1791254255001,"version":"4.1.0"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Hematology patients are highly susceptible to severe bacterial infections, particularly those caused by multidrug-resistant (MDR) gram-negative pathogens, which are associated with significant morbidity and mortality. Eravacycline, a novel fluorocycline antibiotic, demonstrates broad-spectrum activity against MDR bacteria. This real-world study aimed to evaluate the effectiveness and safety of eravacycline in Chinese hematology patients. In this multicenter, retrospective study, hematology patients receiving \u22653 days of eravacycline between September 2023 and September 2024 were included. The outcomes included clinical response rate, microbiological response rate, and safety. Of 796 patients included, most had hematological diseases (94.6%) and recent chemotherapy or radiotherapy (80.2%). The most common infection was pneumonia (57.4%), and sputum (47.2%) was the most frequent specimen type for pathogen isolation. Among 481 patients with microbiological examination results,\n                      <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                      (30.5%) and\n                      <jats:italic toggle=\"yes\">Acinetobacter baumannii<\/jats:italic>\n                      (17.4%) were predominant. The mean time to defervescence was 3.2\u202f\u00b1\u202f2.1 days. The overall clinical response rate was 88.8%, with response rates of 84.0% in bloodstream infections and 87.5% in pulmonary infections. Microbiological response rate at the end of treatment was 90.7%. Eravacycline exhibited high susceptibility rates across\n                      <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                      (95.8%),\n                      <jats:italic toggle=\"yes\">K. pneumonia<\/jats:italic>\n                      e (94.3%), and\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      (100.0%). Only 2.5% of patients reported adverse events. Subgroup analysis showed that pulmonary diseases (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006), sepsis (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003), and duration \u22647 days (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) of eravacycline 1 mg\/kg\/12 h were significantly associated with poorer clinical response rate at the end of treatment. Eravacycline demonstrated promising effectiveness and safety in treating infections of patients from the hematology department.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01287-25","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T14:00:21Z","timestamp":1770127221000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Clinical outcomes and safety of eravacycline in hematology: a multicenter, real-world study"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7846-4544","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051jg5p78","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Hematology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Zhaxin Traditional Chinese & Western Medicine Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0220qvk04","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongmu","family":"Luo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0523vvf33","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Hematology, China Aerospace Science and Industry Corporation 731 Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyin","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04jztag35","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Tong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01b5g4110","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongwen","family":"Sun","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/056swr059","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Xu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Laboratory Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-3863","authenticated-orcid":true,"given":"Depei","family":"Wu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051jg5p78","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Hematology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-021-00702-8"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.02.003"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107186"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2366"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.12.013"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00479-22"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02351-23"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.10.020"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00351-0"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1519"},{"key":"e_1_3_5_15_2","first-page":"1849","article-title":"A randomized, controlled clinical trial on meropenem versus imipenem\/cilastatin for the treatment of bacterial infections","volume":"115","author":"Hou F","year":"2002","unstructured":"Hou F, Li J, Wu G, Zheng B, Chen Y, Gu J, Wang H, Huo L, Xue X, Jia C, Yin Y, Tian X, Ren S. 2002. A randomized, controlled clinical trial on meropenem versus imipenem\/cilastatin for the treatment of bacterial infections. Chin Med J (Engl) 115:1849\u20131854.","journal-title":"Chin Med J (Engl)"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2632-1"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.05.019"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-024-04963-7"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/649865"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)75707-X"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa071"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar3491"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-297"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.10.009"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01287-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01287-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:01:17Z","timestamp":1772632877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01287-25"}},"subtitle":[],"editor":[{"given":"Laurent","family":"Poirel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1128\/aac.01287-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01287-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"2025-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01287-25"}}